Headlines about Cellectar Biosciences (NASDAQ:CLRB) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectar Biosciences earned a news impact score of 0.23 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.3104957619407 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern’s analysis:
- Cellectar Biosciences (CLRB) Stock: Gaining Big On New Data – CNA Finance (press release) (cnafinance.com)
- New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation (finance.yahoo.com)
- Analyzing Cellectar Biosciences (CLRB) & The Competition (americanbankingnews.com)
- Cellectar Biosciences, Inc. (CLRB) – Tracking the Technical Picture – Wall Street Morning (wallstreetmorning.com)
- Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma – GlobeNewswire (press release) (globenewswire.com)
Several equities research analysts have weighed in on CLRB shares. Zacks Investment Research downgraded Cellectar Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. ValuEngine raised Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
Shares of Cellectar Biosciences (NASDAQ CLRB) traded down 1.645% during midday trading on Wednesday, reaching $1.495. The company’s stock had a trading volume of 66,741 shares. Cellectar Biosciences has a 52 week low of $1.12 and a 52 week high of $3.07. The stock’s market capitalization is $20.81 million. The company has a 50 day moving average of $1.71 and a 200-day moving average of $1.69.
Cellectar Biosciences (NASDAQ:CLRB) last announced its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. Equities research analysts predict that Cellectar Biosciences will post ($0.92) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Cellectar Biosciences (CLRB) Stock Price” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://sportsperspectives.com/2017/11/01/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-cellectar-biosciences-clrb-stock-price.html.
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.